Skip to main content

What Bio-Techne's Quarter ended Sep 30, 2026 10-Q says: 2 signals

Bio-Techne filed its latest 10-Q with the SEC on Nov 6, 2026. It discusses acquisition announced and margin pressure.

Public (TECH)Biotechnology Research5,001 to 10,000 employeesbio-techne.comLinkedIn

Get Bio-Techne's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bio-Techne this week? Use Autobound signals for bio-techne.com.
Filed
Nov 6, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
7

Source: Autobound Signal API · 80 signals tracked for Bio-Techne · updated

10-Q · latest 7

What Bio-Techne's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 2 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Mar 31, 2026

    Filed · 3 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Dec 31, 2025

    Filed · 2 signals

    SEC EDGAR

Earnings calls

Bio-Techne earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Emerging biotech sales down high single digits on funding lagRevenues from emerging biotech customers dropped high single digits in Q3 following historical funding constraints. Despite recent rebounds in late-stage funding, early-stage discovery budgets remain suppressed, impacting core reagent demand. Management does not anticipate a meaningful recovery until the first half of fiscal 2027.
Brand realignment streamlines 10 product brands down to 3In April, the company executed a portfolio brand alignment consolidating 10 brands into three: R&D Systems, Bio-Techne Spatial Biology, and Bio-Techne Diagnostics. This strategy aims to simplify customer engagement and workflow integration across research and clinical applications. It also enhances product discoverability across digital and AI-driven platforms.
Spatial Biology grew mid-teens with COMET up over 65%The Spatial Biology portfolio delivered mid-teens revenue growth, powered by more than 65% expansion in the COMET Multiomic Spatial platform. The franchise exited the quarter with another record backlog for COMET and installed its first unit in China, while RNAscope kits achieved high single-digit growth. Sellers targeting lab automation, imaging, or pathology reagent supply chains will find...
Steve Crouse promoted to President of Diagnostics and Spatial BiologySteve Crouse was appointed President of the Diagnostics and Spatial Biology segment after leading the Analytical Solutions unit for five years. Leadership changes often trigger vendor and operational process evaluations within the division. The segment reported $85.6 million in quarterly revenue, up 3% organically.
Adjusted gross margin down 120 bps from unfavorable mixAdjusted gross margin contracted year-over-year to 70.4% from 71.6% due to negative product mix. Adjusted operating margin dropped 70 basis points year-over-year to 34.2% as a result of mix and volume deleverage. Operating margins partially offset the decline through structural streamlining and the Exosome Diagnostics divestiture.
Collaboration with Providence Health and Microsoft on GigaTIME AIThe company highlighted a research collaboration with Providence Health and Microsoft utilizing datasets generated on the COMET spatial biology platform. The joint framework converts traditional H&E pathology images into virtual 3D tissue representations. Management views content-rich biological data as an essential requirement for training healthcare AI models.

Signal API · MCP

Track Bio-Techne with the Signal API

One POST /v1/companies/enrich call with bio-techne.com returns Bio-Techne 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bio-techne.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Bio-Techne 10-Q

When did Bio-Techne file its latest 10-Q?
Bio-Techne filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 6, 2026. The one before it was filed on May 6, 2026.
What did Bio-Techne disclose in its latest 10-Q?
From the filing dated Nov 6, 2026: Merck KGaA acquisition of Bio-Techne approved by shareholders, expected closing late 2026/early 2027
What did Bio-Techne say on its recent earnings calls?
Q3 FY2026: Emerging biotech sales down high single digits on funding lag (dated May 6, 2026).
Where can I read Bio-Techne's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/842023/000110465926123907/tech-20260930x10q.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →